Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2012170495) METHODS FOR REPAIRING TISSUE DAMAGE USING PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2012/170495 International Application No.: PCT/US2012/041054
Publication Date: 13.12.2012 International Filing Date: 06.06.2012
IPC:
A61K 38/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
Applicants:
PROVASCULON, INC. [US/US]; 1 Broadway, 14th Floor Cambridge, MA 02142, US (AllExceptUS)
SANDRASAGRA, Anthony [US/US]; US (UsOnly)
WU, Weitao [CN/US]; US (UsOnly)
Inventors:
SANDRASAGRA, Anthony; US
WU, Weitao; US
Agent:
ELBING, Karen, L.; Clark & Elbing LLP 101 Federal Street Boston, MA 02110, US
Priority Data:
61/494,07907.06.2011US
Title (EN) METHODS FOR REPAIRING TISSUE DAMAGE USING PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1
(FR) PROCÉDÉS DE RÉPARATION DE DOMMAGE TISSULAIRE À L'AIDE DE MUTANTS RÉSISTANT AUX PROTÉASES DU FACTEUR 1 DÉRIVÉ DE CELLULES STROMALES
Abstract:
(EN) The present invention features methods for treating or ameliorating tissue damage using intravenous administration of compositions that include stromal cell derived factor-1 (SDF-1) peptides or mutant SDF-1 peptides that have been mutated to make them resistant to protease digestion, but which retain chemoattractant activity. Systemic delivery, and specifically intravenous ("IV") delivery, of SDF-1 and protease resistant SDF-1 mutants is very effective for the treatment of tissue damage.
(FR) La présente invention concerne des procédés de caractéristiques destinés au traitement ou à l'amélioration de dommage tissulaire à l'aide d'administration intraveineuse de compositions qui incluent des peptides du facteur 1 dérivé de cellules stromales (SDF-1) ou des peptides du SDF-1 mutants qui ont été mutés pour les rendre résistants à la digestion par les protéases, mais qui conservent une activité chimioattractive. L'administration systémique, et en particulier l'administration intraveineuse ("IV"), de SDF-1 et de mutants de SDF-1 résistants aux protéases est très efficace dans le traitement de dommage tissulaire.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA2838155CN103747795US20140199304EP2717894JP2014519514AU2012268078
JP2017114867AU2017213440IN10208/DELNP/2013